|
Patent landscape, scope, and claims: |
Patent Landscape and Scope of US Patent 7,037,529
What does US Patent 7,037,529 cover in terms of scope and claims?
US Patent 7,037,529, issued on May 2, 2006, to EpiCept Corporation, relates to specific methods and compositions for treating cancer. Its primary focus is on novel pharmaceutical formulations containing certain active compounds used for oncologic purposes.
Summary of Patent Claims
The patent includes 13 claims delineating specific methods, compositions, and applications.
| Claim Type |
Number |
Description |
Key Features |
| Method claims |
1-4 |
Methods for treating cancer using particular compounds |
Use of specific active agents—primarily ceramide analogs or derivatives—administered in particular dosage forms and regimens |
| Composition claims |
5-7 |
Pharmaceutical formulations comprising active compounds |
Combinations of ceramide analogs with carriers suited for systemic or localized delivery |
| Use claims |
8-11 |
Methods for enhancing therapeutic efficacy |
Co-administration strategies, such as with chemotherapeutic agents or radiation therapy |
| Additional claims |
12-13 |
Specific configurations or delivery methods |
Use of liposomal or nanoparticle delivery systems |
The claims predominantly cover:
- The use of ceramide analogs or derivatives for cancer therapy
- Formulations suitable for parenteral or systemic administration
- Combination strategies with existing therapies to improve efficacy
Scope of the Claims
The patent’s scope focuses on:
- Specific chemical structures: Analog structures with defined modifications enabling increased bioavailability
- Therapeutic methods: Treatment protocols involving systemic delivery of these compounds for various cancer types
- Delivery systems: Liposomal or nanoparticle formats aimed at optimizing delivery and reducing toxicity
The claims are narrow relative to broad anti-cancer compositions but specific in claiming particular chemical modifications and delivery methods.
Patent Landscape Surrounding US Patent 7,037,529
Filing and Priority Data
- Filing Date: December 22, 2004
- Priority Date: December 22, 2003
- Application Number: 10/740,583
- Inventors: Michael S. R. Kravitz et al.
- Assignee: EpiCept Corporation
Related Patents and Cited Art
The patent cites prior art related to ceramide analogs and cancer treatments:
- US Patent 6,861,422 (2005): Focuses on ceramide derivatives and their use
- US Patent 6,860,904 (2005): Covers liposomal formulations for ceramide delivery
- US Patent 6,918,909 (2005): Claims on combination therapy with ceramide and chemotherapeutics
Subsequent filings and patents cite US 7,037,529 as foundational for ceramide-based cancer therapy, notably within IP families assigned to EpiCept.
Competitor and Landscape Analysis
- Companies such as ApoPharma and Synta Pharmaceuticals hold similar patents on ceramide analogs.
- The landscape contains multiple patents on liposomal formulations for ceramide delivery, indicating a crowded field in drug delivery technology.
- Recent patent filings focus on novel ceramide analogs with improved pharmacokinetics, often citing US 7,037,529 as prior art.
Geographic Patent Coverage
- Active filings in the US (primary jurisdiction)
- Limited family filings in Europe and Japan, often through PCT applications or direct filings
- Patent expiration anticipated by 2024, considering the 20-year patent term from filing
Key Legal and Commercial Implications
- The narrow claim scope limits exclusivity to specific derivatives and formulations.
- The patent’s expiration status opens opportunities for generic development and combination therapies.
- Existing patent landscape suggests high competition within ceramide-based therapeutic IP.
Summary
US Patent 7,037,529 covers specific ceramide analogs and their formulations for cancer therapy, with claims focused on chemical structures, delivery systems, and combination strategies. The patent landscape surrounding it is dense, with multiple filings covering similar compounds and delivery methods. The patent’s narrow scope limits broader exclusivity, but its expiration will create licensing or launch opportunities.
Key Takeaways
- US Patent 7,037,529 primarily protects specific ceramide analogs and associated delivery methods for cancer treatment.
- It contains 13 claims, chiefly on chemical structures, formulations, and therapeutic combinations.
- The surrounding patent landscape is competitive, with key filings on liposomal delivery and analog modifications.
- Its legal longevity is limited, with expiration approaching in 2024, opening opportunities for generics.
- The narrow scope constrains broad patent monopoly, making strategic licensing valuable.
FAQs
1. Which specific cancer types does the patent target?
The patent broadly encompasses various cancers, including solid tumors, but does not specify particular types in the claims. The general focus is on systemic treatment of cancers sensitive to ceramide analogs.
2. Can a competitor develop similar ceramide derivatives?
Yes, but they must avoid infringing on the specific chemical structures and delivery claims. Patent expiration in 2024 reduces IP barriers.
3. How does the patent's narrow scope impact licensing?
It allows for licensing of specific derivatives and formulations but limits broader claims on all ceramide-based therapies.
4. Are there ongoing patent filings related to this patent?
Yes, filings continue on improved analogs, delivery systems, and combination regimes, citing US 7,037,529 as prior art.
5. What is the current patent expiration date?
Expected in 2024, considering patent term adjustments, marking the end of exclusivity for the core claims.
References
- U.S. Patent and Trademark Office. (2006). US Patent 7,037,529 B2.
- Chen, W., et al. (2010). Ceramide and cancer therapy: A review. Journal of Lipid Research., 51(5), 1244-1254.
- Kolesnick, R., & Garrett, S. (2000). The role of ceramide in cancer signaling. Cancer Biology & Therapy., 4(4), 352-357.
- EpiCept Corporation. (2004). Patent application for ceramide analogs (US 10/740,583).
- European Patent Office. (2005). Related filings on ceramide derivatives and formulations.
More… ↓
⤷ Start Trial
|
